<DOC>
	<DOCNO>NCT02949258</DOCNO>
	<brief_summary>Scirrhous gastric cancer , also know linitis plastic Borrmann type 4 , aggressive tumor extremely poor prognosis . Aggressive surgical procedure adjuvant chemotherapy improve survival rate . The purpose study determine whether neoadjuvant Chemotherapy SEEOX regimen via intra-arterial intravenous administration effective treatment Borrmann type 4 gastric cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With SEEOX Regimen Borrmann Type 4 Gastric Cancer</brief_title>
	<detailed_description>Gastric cancer patient diagnose Borrmann type 4 would include study.They would receive 3 cycle neoadjuvant chemotherapy SEEOX regimen via combine intra-arterial intravenous administration . The treatment schedule consist 3 course ( , 2-week administration 1-week withdrawal ) intra-arterial administration oxaliplatin ( 150mg ) , etoposide ( 100mg ) epirubicin ( 30mg ) Seldinger method day 1 oral S-1 ( 120mg ) day 1-14 , follow radical surgery.The efficacy toxicity SEEOX regimen would examine .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>histologically confirm gastric adenocarcinoma ; male female , age 3070 year ; gastroscopy abdominal compute tomography ( CT ) scanconfirmed typical scirrhous gastric cancer ( without definitive ulceration ) invade half stomach ; peritoneal metastasis confirm laparoscopic exploration cytological examination peritoneal wash Douglas pouch ; eastern Cooperative Oncology Group performance status 0 1 ; serious concomitant disease make survival period &lt; 3 year ; prior antitumor therapy ; sign informed consent begin treatment . patient bear surgical procedure ; pregnant lactating woman ; previous cytotoxic chemotherapy , radiotherapy immunotherapy ; peritoneal metastasis distant metastasis ; history another malignancy within last five year ; history uncontrolled seizure , central nervous system disorder psychiatric disability judge Investigator clinically significant precluding inform consent interfere compliance oral drug intake ; clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , New York Heart Association ( NYHA ) grade II great congestive heart failure serious cardiac arrhythmia require medication myocardial infarction within last 12 month ; organ allograft require immunosuppressive therapy ; serious uncontrolled intercurrent infection serious uncontrolled concomitant disease ; moderate severe renal impairment : serum creatinine &gt; 1.5 x upper limit normal ( ULN ) ; hypersensitivity drug study regimen ; unwilling unable comply protocol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>Borrmann type 4</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Intra-arterial administration</keyword>
</DOC>